Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis

Valeria Studer, Silvia Rossi, Caterina Motta, Fabio Buttari, Diego Centonze

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

B cells and/or the enhanced inflammatory milieu in the subarachnoid space are supposed to have a role in cortical pathology of progressive multiple sclerosis (PMS). The efficacy of intravenous rituximab to deplete circulating B cells is remarkable in MS, and its intrathecal delivery could target compartmentalized inflammation in PMS. We describe the central and peripheral effects of repeated intrathecal rituximab administrations in a patient with severe PMS. Peripheral CD20. + B cells were reduced, while oligoclonal bands were unaffected. Several central proinflammatory cytokines, and markers of neurodegeneration were markedly reduced. Central B cells modulation should be investigated in PMS.

Original languageEnglish
Pages (from-to)229-231
Number of pages3
JournalJournal of Neuroimmunology
Volume276
Issue number1-2
DOIs
Publication statusPublished - Nov 15 2014

Fingerprint

Multiple Sclerosis
B-Lymphocytes
Cytokines
Oligoclonal Bands
Subarachnoid Space
Pathology
Inflammation
Rituximab

Keywords

  • B lymphocytes
  • CD20
  • Neurodegeneration

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology
  • Medicine(all)

Cite this

@article{78a5f7d184344b53b335f4e75fa82ecc,
title = "Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis",
abstract = "B cells and/or the enhanced inflammatory milieu in the subarachnoid space are supposed to have a role in cortical pathology of progressive multiple sclerosis (PMS). The efficacy of intravenous rituximab to deplete circulating B cells is remarkable in MS, and its intrathecal delivery could target compartmentalized inflammation in PMS. We describe the central and peripheral effects of repeated intrathecal rituximab administrations in a patient with severe PMS. Peripheral CD20. + B cells were reduced, while oligoclonal bands were unaffected. Several central proinflammatory cytokines, and markers of neurodegeneration were markedly reduced. Central B cells modulation should be investigated in PMS.",
keywords = "B lymphocytes, CD20, Neurodegeneration",
author = "Valeria Studer and Silvia Rossi and Caterina Motta and Fabio Buttari and Diego Centonze",
year = "2014",
month = "11",
day = "15",
doi = "10.1016/j.jneuroim.2014.08.617",
language = "English",
volume = "276",
pages = "229--231",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier Science B.V.",
number = "1-2",

}

TY - JOUR

T1 - Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis

AU - Studer, Valeria

AU - Rossi, Silvia

AU - Motta, Caterina

AU - Buttari, Fabio

AU - Centonze, Diego

PY - 2014/11/15

Y1 - 2014/11/15

N2 - B cells and/or the enhanced inflammatory milieu in the subarachnoid space are supposed to have a role in cortical pathology of progressive multiple sclerosis (PMS). The efficacy of intravenous rituximab to deplete circulating B cells is remarkable in MS, and its intrathecal delivery could target compartmentalized inflammation in PMS. We describe the central and peripheral effects of repeated intrathecal rituximab administrations in a patient with severe PMS. Peripheral CD20. + B cells were reduced, while oligoclonal bands were unaffected. Several central proinflammatory cytokines, and markers of neurodegeneration were markedly reduced. Central B cells modulation should be investigated in PMS.

AB - B cells and/or the enhanced inflammatory milieu in the subarachnoid space are supposed to have a role in cortical pathology of progressive multiple sclerosis (PMS). The efficacy of intravenous rituximab to deplete circulating B cells is remarkable in MS, and its intrathecal delivery could target compartmentalized inflammation in PMS. We describe the central and peripheral effects of repeated intrathecal rituximab administrations in a patient with severe PMS. Peripheral CD20. + B cells were reduced, while oligoclonal bands were unaffected. Several central proinflammatory cytokines, and markers of neurodegeneration were markedly reduced. Central B cells modulation should be investigated in PMS.

KW - B lymphocytes

KW - CD20

KW - Neurodegeneration

UR - http://www.scopus.com/inward/record.url?scp=84908546527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908546527&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2014.08.617

DO - 10.1016/j.jneuroim.2014.08.617

M3 - Article

VL - 276

SP - 229

EP - 231

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -